Monument Therapeutics

Monument Therapeutics is a stratified medicine company, that has developed novel digital biomarkers to improve neuroscience drug development. The company is initially focused on two indications for which there are no approved treatments: cognitive impairment in schizophrenia and post-operative cognitive dysfunction (“POCD”). The opportunity is therefore to follow therapeutics through from R&D to the market, where the biomarkers would serve as companion diagnostics.

Why we like the business

Monument Therapeutics is repurposing drugs in combination with proprietary cognitive stratification tools to identify the patient sub-groups that are most likely to benefit. This contrasts the years of neuroscience drug development that have been plagued by subjective diagnoses and clinical endpoints.